BIIB110 / Biogen, AliveGen - LARVOL DELTA

ALG-801 demonstrates superior therapeutic efficacy in sugen-hypoxia model of pulmonary hypertension (ERS 2025) - "These findings demonstrate that in SuHx PAH model, ALG-801 has a significantly better efficacy than sildenafil or sotatercept. ALG-801 holds a promising potential for treating pulmonary hypertension."

Clinical • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • ACVR2A • TGFB1

AliveGen Receives FDA Orphan Drug Designation for ALG-801 for Pulmonary Arterial Hypertension (Businesswire) - "AliveGen USA Inc...announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the treatment of pulmonary arterial hypertension (PAH), a rare, serious, and life-threatening condition characterized by high blood pressure in the lung arteries that can lead to right-sided heart failure."

Orphan drug • Pulmonary Arterial Hypertension

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ALG-801 in Healthy Postmenopausal Women (ANZCTR) - P1 | N=32 | Completed | Sponsor: AliveGen USA, Inc. | Not yet recruiting ➔ Completed

Trial completion • Osteoporosis